Skip to main content
. 2021 Jul 2;478(13):2517–2531. doi: 10.1042/BCJ20210244

Figure 5. Determination of the IC50 of the validated hits with the fluorescent-based assay.

Figure 5.

(A) PDK1/AKT/Flt dual pathway inhibitor, (B) Ro 08-2750, (C) Cdk4 inhibitor III, (D) beta-lapachone, (E) dihydrotanshinone I, (F) GRL-0617, (G) tanshinone IIA, (H) cryptotanshinone.